海寧皮城(002344.SZ):擬申請註冊發行不超6億元中期票據和不超10億元超短期融資券
格隆匯4月9日丨海寧皮城(002344.SZ)公佈,公司2022年年度股東大會會議決議,同意公司向中國銀行間市場交易商協會申請註冊發行總額不超過人民幣6億元的中期票據、總額不超過人民幣10億元的超短期融資券。現上述中期票據和超短期融資券的註冊有效期即將到期,爲滿足公司生產經營活動的需要,進一步拓寬融資渠道,降低融資成本,公司於2025年4月8日召開第六屆董事會第八次會議,審議通過了《關於發行中期票據的議案》、《關於發行超短期融資券的議案》,公司擬向交易商協會申請註冊發行總額不超過人民幣6億元的中期票據、總額不超過人民幣10億元的超短期融資券,有效期限不超過兩年,可分期發行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.